For the quarter ending 2026-03-31, DTIL made $10,838K in revenue. -$18,441K in net income. Net profit margin of -170.15%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-03-31 |
|---|---|---|---|---|
| Revenue | 10,838 | 34,866* | 13 | 29 |
| Research and development | 13,110 | 13,763* | 13,352 | 13,588 |
| General and administrative | 6,803 | 8,419* | 7,328 | 8,553 |
| Total operating expenses | 19,913 | 22,181* | 20,680 | 22,141 |
| Interest expense | - | - | - | 354 |
| Operating gain | -9,075 | 12,685* | -20,667 | -22,112 |
| Gain from equity method investment | 0 | -6,410* | -591 | 1,342 |
| (loss) gain on changes in other fair value adjustments | -2,951 | -2,735* | -3 | 49 |
| Loss on change in fair value of warrant liability | -7,107 | 14,065* | -1,179 | -804 |
| Interest expense | 311 | 336* | 362 | - |
| Interest income | 999 | 714* | 1,027 | 1,323 |
| Gain (loss) on disposal of assets | 4 | -412* | 3 | -9 |
| Impairment charges | - | 9* | - | - |
| Total other (expense) income | -9,366 | 4,876* | -1,105 | 1,547 |
| (gain) income from continuing operations | - | 17,561* | -21,772 | -20,565 |
| Gain from discontinued operations | - | 221* | - | - |
| Net gain | -18,441 | 17,782 | - | -20,565 |
| Basic EPS | -0.75 | 1.024 | -1.84 | -2.21 |
| Diluted EPS | -0.75 | 1.024 | -1.84 | -2.21 |
| Basic Average Shares | 24,634,443 | 17,368,023 | 11,818,145 | 9,292,066 |
| Diluted Average Shares | 24,634,443 | 17,368,023 | 11,818,145 | 9,292,066 |
PRECISION BIOSCIENCES INC (DTIL)
PRECISION BIOSCIENCES INC (DTIL)